Boobalan Pachaiyappan
Stock Analyst at Roth Capital
(3.19)
# 1,097
Out of 4,876 analysts
15
Total ratings
46.67%
Success rate
5.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRNA Verona Pharma | Reiterates: Buy | $92 → $116 | $93.71 | +23.79% | 2 | Jun 18, 2025 | |
| PYPD PolyPid | Maintains: Buy | $12 → $9 | $3.55 | +153.52% | 2 | Jun 18, 2025 | |
| CAPR Capricor Therapeutics | Reiterates: Buy | $31 | $10.85 | +185.71% | 1 | Jun 17, 2025 | |
| CING Cingulate | Maintains: Buy | $12 → $11 | $4.12 | +166.99% | 2 | May 19, 2025 | |
| CRVO CervoMed | Maintains: Buy | $15 → $20 | $6.72 | +197.62% | 3 | Mar 18, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Initiates: Buy | $7 | $0.32 | +2,070.54% | 1 | Jan 10, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 | $1.99 | +252.64% | 2 | Dec 24, 2024 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $6.95 | +317.27% | 1 | Dec 5, 2024 | |
| LGVN Longeveron | Initiates: Buy | $10 | $1.37 | +629.93% | 1 | Dec 5, 2024 |
Verona Pharma
Jun 18, 2025
Reiterates: Buy
Price Target: $92 → $116
Current: $93.71
Upside: +23.79%
PolyPid
Jun 18, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $3.55
Upside: +153.52%
Capricor Therapeutics
Jun 17, 2025
Reiterates: Buy
Price Target: $31
Current: $10.85
Upside: +185.71%
Cingulate
May 19, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $4.12
Upside: +166.99%
CervoMed
Mar 18, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $6.72
Upside: +197.62%
Reviva Pharmaceuticals Holdings
Jan 10, 2025
Initiates: Buy
Price Target: $7
Current: $0.32
Upside: +2,070.54%
Gain Therapeutics
Dec 24, 2024
Maintains: Buy
Price Target: $7
Current: $1.99
Upside: +252.64%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $6.95
Upside: +317.27%
Longeveron
Dec 5, 2024
Initiates: Buy
Price Target: $10
Current: $1.37
Upside: +629.93%